Alnylam Pharmaceuticals, Inc.
|Company Name||Alnylam Pharmaceuticals, Inc.|
The investigation concerns whether the Company overstated the efficacy and safety of Alnylam’s lipid complex injection ONPATTRO. And, the Company’s shares fell following news that a FDA review document highlighted specific risks associated with ONPATTRO following the cardiac deaths in patients treated with ONPATTRO.
Submit Your Information
If you suffered a loss on your Alnylam Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.